[Impact of sequential targeted therapy on progression-free survival in metastatic renal cell carcinoma]

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Metastatic renal cell carcinoma (mRCC) presents a significant clinical challenge.
• Sequential targeted therapies are increasingly used in mRCC treatment.
• Optimizing treatment sequences is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the impact of sequential targeted therapy on progression-free survival (PFS) in metastatic renal cell carcinoma.
• To compare the efficacy of different sequences of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) and everolimus.

Main Methods:

• Retrospective study of 17 mRCC patients treated between January 2008 and April 2014.
• Patients received at least two lines of VEGFR-TKI and everolimus therapy.
• Analysis of total PFS and PFS for each therapeutic sequence using Kaplan-Meier and Cox regression.

Main Results:

• Sequential targeted therapies significantly affected total PFS (18.0 vs 46.0 months, P = 0.015).
• The VEGFR-TKI/mTOR inhibitor/VEGFR-TKI (TMT) sequence demonstrated a trend towards improved PFS compared to VEGFR-TKI/VEGFR-TKI/mTOR inhibitor (TTM).
• Hazard ratio (HR) for TTM over TMT was 5.44 (95% CI 1.18-25.06).

Conclusions:

• The sequence of targeted therapy administration impacts PFS in mRCC.
• The TMT sequence (VEGFR-TKI/mTOR inhibitor/VEGFR-TKI) may prolong total PFS in metastatic renal cell carcinoma patients.
• Further prospective studies are warranted to confirm these findings.